MedCap (Q4 review): Beat on Solid Organic Growth - Redeye

Redeye updates its estimates and valuation following MedCap’s Q4 2025 report. Both sales and adjusted EBITA beat our forecasts. The organic growth rate of 10% y/y represented another continued sequential improvement. Medtech had an impressive organic growth of 24%. Speciality Pharma underperformed, but management expects investments in new drugs to lift sales from H2 2026. Comparables for Q1 are relatively soft.

Länk till analysen i sin helhet: https://www.redeye.se/research/1148546/medcap-q4-review-beat-on-solid-organic-growth?utm_source=finwire&utm_medium=RSS